We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
biotechs: Archive
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
by Zacks Equity Research
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GRTSPositive Net Change
biotechs medical vaccines
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
by Zacks Equity Research
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
BMYPositive Net Change VNDAPositive Net Change VERVNegative Net Change IRONPositive Net Change
biotechnology biotechs pharmaceuticals
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
by Zacks Equity Research
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.
ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change AMLXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
by Zacks Equity Research
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
LGNDPositive Net Change AMRNPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechs medical
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
by Zacks Equity Research
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
REGNNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
by Zacks Equity Research
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
MRKPositive Net Change LGNDPositive Net Change ANIPPositive Net Change KTRANegative Net Change
biotechs
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
by Zacks Equity Research
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
AZNPositive Net Change RHHBYPositive Net Change MRKPositive Net Change GNPXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ALLKPositive Net Change
biotechs medical
How Adverum (ADVM) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ADVMNegative Net Change
biotechs medical
Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder
by Zacks Equity Research
Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.
LGNDPositive Net Change VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechs
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
by Zacks Equity Research
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change RCKTNegative Net Change
biotechs gene-therapy medical
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
by Zacks Equity Research
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
ACETNegative Net Change ADMAPositive Net Change FGENPositive Net Change EVAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel
AMGNPositive Net Change VNDAPositive Net Change ADMAPositive Net Change MORNegative Net Change
biotechs
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
BMYPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs medical pharmaceuticals
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
by Zacks Equity Research
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change IRONPositive Net Change
biotechnology biotechs pharmaceuticals
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
by Zacks Equity Research
Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
VRTXNegative Net Change ANIPPositive Net Change ADMAPositive Net Change CRSPPositive Net Change
biotechs gene-therapy medical messenger-rna pharmaceuticals
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change SLDBPositive Net Change
biotechs
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
by Zacks Equity Research
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
JAZZPositive Net Change ANIPPositive Net Change ADMAPositive Net Change AXSMPositive Net Change
biotechs
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
by Zacks Equity Research
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
BMYPositive Net Change PFEPositive Net Change ABBVNegative Net Change ADMAPositive Net Change
biotechs medical pharmaceuticals
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change KODPositive Net Change
biotechs earnings
Stock Market News for Apr 1, 2024
by Zacks Equity Research
U.S. stock markets closed mixed on Thursday to end a fascinating first quarter of 2024.
MRNAPositive Net Change
biotechs
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
NVOPositive Net Change LLYPositive Net Change IBBPositive Net Change VKTXPositive Net Change XBIPositive Net Change MDGLNegative Net Change
biotechnology biotechs pharmaceuticals
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
by Zacks Equity Research
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechs medical messenger-rna vaccines
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
by Zacks Equity Research
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
ACETNegative Net Change ADMAPositive Net Change FGENPositive Net Change APGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
VNDAPositive Net Change ADMAPositive Net Change SNDXPositive Net Change MORNegative Net Change
biotechs